Sort   by:  
 Page size 
UnknownGreen synthesis and characterization of copper nanoparticles for investigating their effect on germination and growth of wheat.
Today, different types of nanoparticles (NPs) are being synthesized and used for medical and agricultural applications. In this study, copper nanoparticles (CuNPs) were synthesized using the aqueous extract of mint (Mentha longifolia L.). For the characterization of CuNPs, UV-visible spectroscopy, s...
S-EPMC9212164 | biostudies-literature
UnknownBurnout among surgeons before and during the SARS-CoV-2 pandemic: an international survey.

Background

SARS-CoV-2 pandemic has had many significant impacts within the surgical realm, and surgeons have been obligated to reconsider almost every aspect of daily clinical practice.

Methods

This is a cross-sectional study reported in compliance with the CHERRIES guidelines and con...
S-EPMC10810224 | biostudies-literature
UnknownComparison of film and digital fundus photographs in eyes of individuals with diabetes mellitus.

Purpose

To compare grading of diabetic retinopathy (DR) and diabetic macular edema (DME) from stereoscopic film versus stereoscopic digital photographs obtained from a subset of Diabetic Retinopathy Clinical Research Network (DRCR.net) participants.

Methods

In this photographic media ...
S-EPMC3176025 | biostudies-literature
UnknownSCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design.

Purpose

To evaluate the incidence of intravitreal silicone oil (SO) droplets associated with intravitreal injections using a staked-on vs luer cone syringe design in the SCORE (Standard Care vs COrticosteroid in REtinal Vein Occlusion) Study.

Design

Prospective, randomized, phase III ...
S-EPMC2780008 | biostudies-literature
UnknownComparison of short-term outcomes from the International Oesophago-Gastric Anastomosis Audit (OGAA), the Esophagectomy Complications Consensus Group (ECCG), and the Dutch Upper Gastrointestinal Cancer Audit (DUCA).

Background

The Esophagectomy Complications Consensus Group (ECCG) and the Dutch Upper Gastrointestinal Cancer Audit (DUCA) have set standards in reporting outcomes after oesophagectomy. Reporting outcomes from selected high-volume centres or centralized national cancer programmes may not, ho...
S-EPMC8140199 | biostudies-literature
UnknownImpact of the COVID-19 pandemic on patients with paediatric cancer in low-income, middle-income and high-income countries: a multicentre, international, observational cohort study.

Objectives

Paediatric cancer is a leading cause of death for children. Children in low-income and middle-income countries (LMICs) were four times more likely to die than children in high-income countries (HICs). This study aimed to test the hypothesis that the COVID-19 pandemic had affected ...
S-EPMC9021459 | biostudies-literature
UnknownPostoperative outcomes in oesophagectomy with trainee involvement.

Background

The complexity of oesophageal surgery and the significant risk of morbidity necessitates that oesophagectomy is predominantly performed by a consultant surgeon, or a senior trainee under their supervision. The aim of this study was to determine the impact of trainee involvement in...
S-EPMC8763367 | biostudies-literature
UnknownAssociation of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.

Importance

Comparisons of the relative effect of 3 anti-vascular endothelial growth factor agents to treat diabetic macular edema warrant further assessment.

Objective

To provide additional outcomes from a randomized trial evaluating 3 anti-vascular endothelial growth factor agents fo...
S-EPMC5567793 | biostudies-literature
UnknownAflibercept, bevacizumab, or ranibizumab for diabetic macular edema.

Background

The relative efficacy and safety of intravitreous aflibercept, bevacizumab, and ranibizumab in the treatment of diabetic macular edema are unknown.

Methods

At 89 clinical sites, we randomly assigned 660 adults (mean age, 61±10 years) with diabetic macular edema involving th...
S-EPMC4422053 | biostudies-literature
UnknownPlasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
PURPOSE:To assess systemic vascular endothelial growth factor (VEGF)-A levels after treatment with intravitreous aflibercept, bevacizumab, or ranibizumab. DESIGN:Comparative-effectiveness trial with participants randomly assigned to 2 mg aflibercept, 1.25 mg bevacizumab, or 0.3 mg ranibizumab after ...
S-EPMC6568257 | biostudies-literature
Sort   by:  
 Page size